PRGO - Perrigo Cuts Annual Guidance This OTC Drug Firm Also Reports Mixed Q3 Earnings | Benzinga
Perrigo Company PLC (NYSE: PRGO) reported third-quarter sales of $1.12 billion, up 2.2% Y/Y, missing the consensus of $1.20 billion, driven primarily by the acquisition of the Gateway infant formula facility and the U.S. and Canadian Good Start infant formula brand.
The company reported adjusted EPS of $0.64 compared to $0.56 a year ago, beating the consensus of $0.61.
Also Read: First Birth Control Pill For OTC Use In US Lands ...